Company intelligence / Profile preview

Shanghai Model Organisms Center

Shanghai, Shanghai, Chinamodelorg.us ↗

Ownership: Private
Employees: ~777
Development stage: Commercial

Overview

Shanghai Model Organisms Center provides a broad range of genetically modified animal and cell models for preclinical research. The company supports drug discovery and development with advanced gene editing technologies and offers preclinical services such as toxicology, pharmacokinetics, phenotype analysis, and pharmacodynamics. It is not a therapeutics developer but an enabler for the life sciences industry.

Therapeutic areas: GastroenterologyOncologyImmunologyNeurology
Modalities: Genetically engineered animal modelsGene editing technology (including CRISPR)Cell models
Industry: Non-Drug Biotech

Partnerships

Not specifically listed in public sources; company is recognized as a key supplier to global pharmaceutical and biotech companies.

Beyond the preview

Go deeper on Shanghai Model Organisms Center.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Model Organisms Center.

Explore the full profile